Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial

BACKGROUND: Conestat alfa (ConA), a recombinant human C1 inhibitor, may prevent thromboinflammation. METHODS: We conducted a randomized, open-label, multi-national clinical trial in which hospitalized adults at risk for progression to severe COVID-19 were assigned in a 2:1 ratio to receive either 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Urwyler, Pascal, Leimbacher, Marina, Charitos, Panteleimon, Moser, Stephan, Heijnen, Ingmar A. F. M., Trendelenburg, Marten, Thoma, Reto, Sumer, Johannes, Camacho-Ortiz, Adrián, Bacci, Marcelo R., Huber, Lars C., Stüssi-Helbling, Melina, Albrich, Werner C., Sendi, Parham, Osthoff, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641758/
https://www.ncbi.nlm.nih.gov/pubmed/37965347
http://dx.doi.org/10.3389/fimmu.2023.1255292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641758/
https://www.ncbi.nlm.nih.gov/pubmed/37965347
http://dx.doi.org/10.3389/fimmu.2023.1255292

Ejemplares similares